Rxo (RXO) Accumulated Expenses (2021 - 2026)

Rxo (RXO) has reported Accumulated Expenses for 6 consecutive years, with $367.0 million the latest figure, recorded in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $367.0 million, up 2.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $367.0 million (up 2.51% YoY), and the FY2025 annual result was $397.0 million, up 6.43% from the prior year.
• Accumulated Expenses was $367.0 million for Q1 2026 at Rxo, down from $397.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $397.0 million in Q4 2025 and troughed at $197.0 million in Q2 2024.
• Average Accumulated Expenses over 5 years is $283.0 million, with a median of $265.0 million recorded in 2023.
• Year-over-year, Accumulated Expenses retreated 22.27% in 2023 and jumped 87.44% in 2024.
• Over 5 years, Accumulated Expenses stood at $256.0 million in 2022, then declined by 22.27% to $199.0 million in 2023, then surged by 87.44% to $373.0 million in 2024, then grew by 6.43% to $397.0 million in 2025, then retreated by 7.56% to $367.0 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $367.0 million in Q1 2026, $397.0 million in Q4 2025, and $321.0 million in Q3 2025.